Selected Techniques for Delivery of Drugs to the Brain (CPB 0731, reviewed 2025-11-26)
Effective date
Not stated in the notice
Identified
Aug 16, 2026
Summary
Aetna considers convection-enhanced delivery of drugs into the brain parenchyma experimental, investigational, or unproven. Aetna also considers low-intensity MR-guided focused ultrasound (MRgFUS) mediated disruption of the blood-brain barrier for enhanced drug delivery into the brain experimental, because the safety and effectiveness of these approaches have not been established. CPT code 0947T for MRgFUS stereotactic blood-brain barrier disruption is not covered for the indications listed, and ICD-10 codes for brain malignancies, Alzheimer's disease, epilepsy and seizures are listed as not covered.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.
01Billing team: do not bill convection-enhanced delivery or low-intensity MRgFUS blood-brain barrier disruption for enhanced drug delivery as covered services, because the policy considers both experimental, investigational, or unproven.
02CPT 0947T is not covered for the indications listed.
03Claims for 0947T with ICD-10 codes C71.0 to C71.9, C79.31, C79.49, G30.0 to G30.9, G40.001 to G40.909, R56.1 or R56.9 will not be covered.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.